Pfizer says COVID-19 vaccine “highly effective” against Delta variants

Katherine Shagoury

June 28, 2021
Mufid Majnun/Unsplash

The Pfizer/BioNTech novel coronavirus (COVID-19) vaccination is “highly effective” against the Delta variant, Reuters reported late last week.

The variant, which was first identified in India, has become the predominant strain in England and other countries, and is on track to become the predominant strain in the United States, researchers said.

A recent study by researchers at the University of Texas with Pfizer/BioNtech published in the journal Nature found that antibodies elicited by the vaccine were still able to neutralize all tested variants, including Delta, but at reduced strength. Additionally, an analysis by Public Health England found that both the Pfizer/BioNTech and AstraZeneca vaccines provide more than 90 percent protection against hospitalization from the Delta variant. More research is needed.

Editor's note: Click here for more information and ongoing COVID-19 updates for integrative healthcare professionals.

About the Author:

Katherine Shagoury

Katherine Shagoury

Katherine Shagoury is the editor of Integrative Practitioner. She brings a decade of experience creating and managing content for national healthcare audiences as a digital editor and professional journalist, including serving as managing editor for a popular medical billing and coding association and as a reporter for the Boston Globe, Boston.com, and USA Today. A certified personal trainer and nutrition coach with the National Academy of Sports Medicine, a certified group fitness instructor with the Athletics and Fitness Association of America, a certified barre instructor, and a TRX qualified trainer, her passion for and commitment to healthy living fuels her enthusiasm for supporting the integrative healthcare community.

© 2024 Diversified Communications. All rights reserved.
Diversified Communications